As of 29 March 2021 , at 04:32 pm GMT+2, the world has recorded 126 890 643 confirmed COVID-19 cases and 2 778 619 deaths. The last worldwid...
- Advertisement -
As of 29 March 2021, at 04:32 pm GMT+2, the world has recorded 126 890 643 confirmed COVID-19 cases and 2 778 619 deaths. The last worldwide COVID-19 vaccine doses stood at 462,824,374 as of 24 March 2021.
Different COVID-19 vaccines intending to provide acquired immunity against the acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing coronavirus disease 2019 (COVID-19).
By @Comic24Derick
According to the World Health Organisation (WHO), “vaccines save millions of lives each year and they work by training and preparing the body’s natural defences, the immune system to recognise and fight off the viruses and bacteria they target.”
“After vaccination, of the body, is later exposed to those disease-causing germs, the body is immediately ready to destroy them, preventing illness.” At least seven different vaccines across three platforms have been rolled out in countries, said the WHO.
“At the same time, more than 200 additional vaccine candidates are in development, of which more than 60 are in clinical development. COVAX is part of the ACT Accelerator, which WHO launched with partners in 2020,” the WHO announced.
In America, there are three authorised and recommended vaccines to prevent COVID-19. The Pfizer-BioNTech COVID-19 Vaccine (BNT162b2), manufactured by Pfizer, Inc., and BioNTech (mRNA). A person is given 2 shots, 21 days apart in the muscle of the upper body. The vaccine does not contain eggs, preservatives, or latex.
The Moderna COVID-19 Vaccine (mRNA-1273) was manufactured by ModernaTX, Inc. Recipients receive 2 shots, one month (28 days) apart in the muscle of the upper arm. The Johnson & Johnson’s Janssen COVID-19 Vaccine (JNJ-78436735) was developed by Janssen Pharmaceuticals Companies of Johnson & Johnson is administered as a single dose in the muscle of the upper arm.
On March 11, Maryland based Novavax released one of its phased 3 clinical trials for NVX-CoV2373. The vaccine was “found to be 96 percent effective against the original strain of the virus, though it was less effective against newer viral strains.”
Sinovac Biotech named its product CoronaVac with limited use in China, Hong Kong, Thailand, and Indonesia. Chinese firm Sinovac Biotech received emergency approval to begin immunising high-risk groups such as healthcare workers this summer. CoronaVac is made from an activated, or “killed,” form of SARS-CoV-2 that is refrigerated and delivered in two doses separated by two weeks.
The BBIBP-CorV vaccine was developed by state-owned Chinese pharmaceutical company Sinopharm and was approved in China, U.A.E., Bahrain, and Egypt. The vaccine given in two doses was approved in China for high-risk groups such as healthcare workers.
“After vaccination, of the body, is later exposed to those disease-causing germs, the body is immediately ready to destroy them, preventing illness.” At least seven different vaccines across three platforms have been rolled out in countries, said the WHO.
“At the same time, more than 200 additional vaccine candidates are in development, of which more than 60 are in clinical development. COVAX is part of the ACT Accelerator, which WHO launched with partners in 2020,” the WHO announced.
 |
| Know Your Vaccine's Origi, Status Before You Recieve it |
The Moderna COVID-19 Vaccine (mRNA-1273) was manufactured by ModernaTX, Inc. Recipients receive 2 shots, one month (28 days) apart in the muscle of the upper arm. The Johnson & Johnson’s Janssen COVID-19 Vaccine (JNJ-78436735) was developed by Janssen Pharmaceuticals Companies of Johnson & Johnson is administered as a single dose in the muscle of the upper arm.
On March 11, Maryland based Novavax released one of its phased 3 clinical trials for NVX-CoV2373. The vaccine was “found to be 96 percent effective against the original strain of the virus, though it was less effective against newer viral strains.”
Sinovac Biotech named its product CoronaVac with limited use in China, Hong Kong, Thailand, and Indonesia. Chinese firm Sinovac Biotech received emergency approval to begin immunising high-risk groups such as healthcare workers this summer. CoronaVac is made from an activated, or “killed,” form of SARS-CoV-2 that is refrigerated and delivered in two doses separated by two weeks.
The BBIBP-CorV vaccine was developed by state-owned Chinese pharmaceutical company Sinopharm and was approved in China, U.A.E., Bahrain, and Egypt. The vaccine given in two doses was approved in China for high-risk groups such as healthcare workers.
Scientists across the globe are collaborating to bring tests, treatments and vaccines in a bid to save lives during the pandemic, however, all other COVID1- precautions must remain in place.
- Advertisement -
- Advertisement -
Tinzwei Is A Worth Voyage For Those In Pursuit For Up-To-Date World Events.
Read More At The Online Coronavirus Portal Or Use The 24-Hour Public Hotline:
South Africa: 0800 029 999 or just Send Hie to 0600 123 456 on WhatsApp
No comments